Targeted immune cell therapy for Claudin18.2-positive advanced pancreatic cancer
Part of Cancer clinical trials.
This early-phase trial is testing a new kind of immune cell therapy—dendritic cells and CAR-T cells—that specifically targets a protein called Claudin18.2 on your cancer cells. It is for people with advanced pancreatic cancer who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that has been confirmed by a biopsy or cytology test.
- Your tumor must have a protein called Claudin18.2 (at moderate or high levels).
- You have tried at least two standard treatments or have decided not to receive chemotherapy.
- You are between 18 and 80 years old and are able to perform most daily activities on your own.
- Your blood counts (white cells, red cells, platelets) and organ function (liver, kidneys) are adequate as per lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This trial tests a special type of immune therapy called CAR-T, which uses your own blood cells to attack cancer cells that have a specific marker, Claudin 18.2. It may be an option for people with advanced solid tumors (especially pancreatic cancer) that have not responded to other treatments.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.